| A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy X Du, F Tang, M Liu, J Su, Y Zhang, W Wu, M Devenport, CA Lazarski, ... Cell research 28 (4), 416-432, 2018 | 233 | 2018 |
| Intratumoral delivery of IL-21 overcomes anti-Her2/Neu resistance through shifting tumor-associated macrophages from M2 to M1 phenotype M Xu, M Liu, X Du, S Li, H Li, X Li, Y Li, Y Wang, Z Qin, YX Fu, S Wang The Journal of Immunology 194 (10), 4997-5006, 2015 | 136 | 2015 |
| Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice X Du, M Liu, J Su, P Zhang, F Tang, P Ye, M Devenport, X Wang, Y Zhang, ... Cell research 28 (4), 433-447, 2018 | 108 | 2018 |
| Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade? F Tang, X Du, M Liu, P Zheng, Y Liu Cell & Bioscience 8, 1-3, 2018 | 106 | 2018 |
| Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy Y Liu, P Zheng Trends in pharmacological sciences 41 (1), 4-12, 2020 | 104 | 2020 |
| The efficacy of oncolytic adenovirus is mediated by T-cell responses against virus and tumor in Syrian hamster model X Li, P Wang, H Li, X Du, M Liu, Q Huang, Y Wang, S Wang Clinical Cancer Research 23 (1), 239-249, 2017 | 89 | 2017 |
| Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy Y Zhang, X Du, M Liu, F Tang, P Zhang, C Ai, JK Fields, EJ Sundberg, ... Cell Research 29 (8), 609-627, 2019 | 86 | 2019 |
| Expression of the galectin-9‑Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma Z Liu, H Han, X He, S Li, C Wu, C Yu, S Wang Oncology Letters 11 (3), 1829-1834, 2016 | 81 | 2016 |
| How does an anti-CTLA-4 antibody promote cancer immunity? Y Liu, P Zheng Trends in immunology 39 (12), 953-956, 2018 | 72 | 2018 |
| Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses L Cheng*, X Du*, Z Wang, J Ju, M Jia, Q Huang, Q Xing, M Xu, Y Tan, ... Journal of hepatology 61 (6), 1297-1303, 2014 | 54 | 2014 |
| Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues CM Bailey, Y Liu, M Liu, X Du, M Devenport, P Zheng, Y Liu, Y Wang The Journal of Clinical Investigation 132 (9), 2022 | 49 | 2022 |
| CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder X Wang, M Liu, J Zhang, NK Brown, P Zhang, Y Zhang, H Liu, X Du, W Wu, ... Cell metabolism 34 (8), 1088-1103. e6, 2022 | 23 | 2022 |
| The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody M Xu, X Du, M Liu, S Li, X Li, YX Fu, S Wang Protein & cell 3, 441-449, 2012 | 15 | 2012 |
| Mechanism-and immune landscape-based ranking of therapeutic responsiveness of 22 major human cancers to next generation anti-CTLA-4 antibodies P Zhang, X Xiong, C Rolfo, X Du, Y Zhang, H Yang, A Russo, ... Cancers 12 (2), 284, 2020 | 13 | 2020 |
| CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect M Liu, X Wang, X Du, Y Zhang, C Ai, S Hu-Lieskovan, T Li, M Devenport, ... Signal Transduction and Targeted Therapy 7 (1), 224, 2022 | 9 | 2022 |
| S-15 in combination of Akt inhibitor promotes the expansion of CD45RA−CCR7+ tumor infiltrating lymphocytes with high cytotoxic potential and downregulating PD-1+Tim-3 … B Xu, L Yuan, G Chen, T Li, J Zhou, C Zhang, P Qin, MM Muthana, ... Cancer Cell International 19, 1-11, 2019 | 5 | 2019 |
| Immunotherapy of metastatic and autochthonous liver cancer with IL-15/IL-15Rα fusion protein L Cheng*, X Du*, L Su, S Wang Oncoimmunology 3 (11), e963409, 2014 | 4 | 2014 |
| Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4–and PD-1–targeted immunotherapy M Liu, X Wang, X Du, W Wu, Y Zhang, P Zhang, C Ai, M Devenport, J Su, ... Science translational medicine 15 (685), eabm5663, 2023 | 3 | 2023 |
| Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy Y Liu, P Zheng, F Tang, LIU Mingyue, M Devenport, DU Xuexiang, ... | 3 | 2019 |
| CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment MM Muthana, X Du, M Liu, X Wang, W Wu, C Ai, L Su, P Zheng, Y Liu Elife 12, RP87281, 2023 | 2 | 2023 |
Mingyue LiuUniversity of Maryland School of MedicineVerified email at ihv.umaryland.edu
